EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of homologous and heterologous inactivated and mRNA vaccination programme against SARS‐CoV ‐2 in dialysis patients

Emre Yasar iD, Yesim Yildiz, Erensu Ozturk, Ebru Gok Oguz, Ezgi Coskun Yenigun, Ramazan Ozturk, Ozant Helvaci, Hasan Selcuk Ozger iD, Meryem Keles, Cengiz Karacin, Asiye Ugras Dikmen, Kayhan Caglar und 6 weitere

Nephrology · 2024

DOI: 10.1111/nep.14292 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Nephrology, 2024. Verfasst von Emre Yasar und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Gazi University, Faculty of Medicine, Ankara, Turkey. Hauptthemen laut MEDLINE: COVID-19, Renal Dialysis, BNT162 Vaccine, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Gazi Üniversitesi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the vaccine response and the effect of the booster dose on COVID‐19 positivity in haemodialysis (HD) and peritoneal dialysis (PD) patients who received and did not receive BNT162b2 as a booster dose after two doses of CoronaVac.

Methods

The study included 80 PD and 163 HD patients, who had been administered two doses of the CoronaVac. Antibody levels were measured on Days 42 and 90 after the first dose. Measurements were repeated on Day 181 after the first dose in the patients that received two vaccine doses and on Day 28 after the third dose in those that also received the booster dose. Antibody levels below 50 AU/mL were considered negative.

Results

The seropositivity rate was similar in the HD and PD group on Days 42 and 90 ( p = 0.212 and 0.720). All patients were seropositive in the booster group. The antibody level was lower in the patients that received CoronaVac as the booster compared to those administered BNT162b2 in HD and PD groups ( p < 0.001 and 0.002). COVID‐19 positivity was detected in 11 patients (7 = had not received the booster dose, 4 = had received third dose of CoronaVac). The multivariate analysis revealed that as age increased, COVID‐19 positivity also increased (OR: 1.080, 95% CI: 1.017 – 1.146, p = 0.012), while booster dose administration decreased this positivity (OR: 0.113, 95% CI: 0.028 – 0.457, p = 0.002).

Conclusion

Our results may indicate the need for additional vaccination doses in patients with HD and PD. Our findings indicate a higher antibody response in dialysis patients with heterologous BNT162b2 as a booster dose after two doses of CoronaVac compared to homologous CoronaVac. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Renal DialysisBNT162 VaccineSARS-CoV-2COVID-19 VaccinesHumansMaleFemaleMiddle AgedAgedImmunization, SecondaryAntibodies, ViralPeritoneal DialysisVaccinationVaccines, InactivatedAdult

Stichwörter der Autor:innen

COVID‐19antibody levelshaemodialysisperitoneal dialysisvaccination

Substanzen

BNT162 VaccineCOVID-19 VaccinesAntibodies, ViralVaccines, Inactivated

Autor:innen und Institutionen

  • Department of Nephrology, Gazi University, Faculty of Medicine, Ankara, Turkey.
  • Department of Infectious Disease and Clinical Microbiology, Gazi University Faculty of Medicine, Ankara, Turkey.
  • Department of Medical Microbiology, Gazi University Faculty of Medicine, Ankara, Turkey.
  • Department of Nephrology, University of Health Sciences, Etlik Ihtisas Training & Research Hospital, Ankara, Turkey.
  • Department of Nephrology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.
  • Department of Nephrology, University of Health Sciences, Ankara Training & Research Hospital, Ankara, Turkey.

ORCID-Profile: Emre Yasar, Hasan Selcuk Ozger

Förderung

  • Gazi Üniversitesi

Zitieren

APA

Yasar, E., Yildiz, Y., Ozturk, E., Gok Oguz, E., Coskun Yenigun, E., Ozturk, R., Helvaci, O., Ozger, H. S., Keles, M., Karacin, C., Ugras Dikmen, A., Caglar, K., Duranay, M., Ayli, M. D., Dizbay, M., Erten, Y., Guz, G., & Derici, U. (2024). Comparison of homologous and heterologous inactivated and mRNA vaccination programme against SARS‐CoV ‐2 in dialysis patients. Nephrology. https://doi.org/10.1111/nep.14292

Vancouver

Yasar E, Yildiz Y, Ozturk E, Gok Oguz E, Coskun Yenigun E, Ozturk R, et al. Comparison of homologous and heterologous inactivated and mRNA vaccination programme against SARS‐CoV ‐2 in dialysis patients. Nephrology. 2024. doi:10.1111/nep.14292

BibTeX
@article{Yasar2024,
  author = {Yasar, Emre and Yildiz, Yesim and Ozturk, Erensu and Gok Oguz, Ebru and Coskun Yenigun, Ezgi and Ozturk, Ramazan and Helvaci, Ozant and Ozger, Hasan Selcuk and Keles, Meryem and Karacin, Cengiz and Ugras Dikmen, Asiye and Caglar, Kayhan and Duranay, Murat and Ayli, Mehmet Deniz and Dizbay, Murat and Erten, Yasemin and Guz, Galip and Derici, Ulver},
  title = {Comparison of homologous and heterologous inactivated and mRNA vaccination programme against SARS‐CoV ‐2 in dialysis patients},
  journal = {Nephrology},
  year = {2024},
  doi = {10.1111/nep.14292}
}
Kostenlos starten →